Open Access. Powered by Scholars. Published by Universities.®
- Discipline
- Keyword
-
- Life Sciences & Biomedicine (8)
- Science & Technology (8)
- Pathology (3)
- CANCER (2)
- Genetics & Heredity (2)
-
- Medicine (2)
- 2-diolate;; VEGF (1)
- 3q29 microdeletion (1)
- 5-Fluorouracil (1)
- 80 and over;; Female;; Humans;; Lymphoma (1)
- AMERICAN-PATHOLOGISTS (1)
- AML (1)
- ANTIGEN-DETECTION TEST (1)
- Acute myeloid leukemia;; APRI (1)
- Adenocarcinoma in situ;; aggressive digital papillary adenocarcinoma;; apocrine gland;; eccrine gland;; papillary eccrine adenoma (1)
- Adenocarcinoma/genetics/ metabolism;; Animals;; Cell Growth Processes/genetics;; Cell Line (1)
- Aged;; Aged (1)
- And Serous/diagnosis/genetics;; Neuroendocrine Tumors/diagnosis/genetics;; Pancreatic Neoplasms/diagnosis/*genetics (1)
- And;; Oxaliplatin;; GO (1)
- Androgen/genetics/ metabolism;; Receptors (1)
- Animals;; Carcinoma (1)
- Aspartate aminotransferase to platelet ratio;; AST (1)
- Aspartate aminotransferase;; Bmab (1)
- Astrocytoma (1)
- BARDET-BIEDL-SYNDROME (1)
- BD VERITOR SYSTEM (1)
- Bevacizumab;; Colorectal cancer;; DF (1)
- Business;; genomics;; informatics;; next-generation sequencing;; personalized medicine;; HEALTH-CARE;; MEDICINE;; Genetics & Heredity (1)
- CELL TRANSPLANT RECIPIENTS (1)
- CHROMOSOMAL MICROARRAY (1)
Articles 61 - 66 of 66
Full-Text Articles in Pathology
Aggressive Renal Angiomyolipoma Of The Lipomatous Variant With Inferior Vena Cava Thrombus: A Case Report And Review Of The Literature, C. Fox, S. S. Salami, D. M. Moreira, G. S. Landis, D. Chan, O. Yaskiv, M. A. Vira
Aggressive Renal Angiomyolipoma Of The Lipomatous Variant With Inferior Vena Cava Thrombus: A Case Report And Review Of The Literature, C. Fox, S. S. Salami, D. M. Moreira, G. S. Landis, D. Chan, O. Yaskiv, M. A. Vira
Journal Articles
Two variants of renal angiomyolipoma (AML)—classic and epithelioid—have been described. Although the epithelioid variant has been reported to demonstrate an aggressive clinical behavior, classic AML is usually benign. Herein, we report a case of a 42-year-old asymptomatic woman with a lipomatous variant of renal AML associated with an inferior vena cava thrombus managed with radical nephrectomy and caval thrombectomy.
Mantle Cell Lymphoma With In Situ Or Mantle Zone Growth Pattern: A Study Of Five Cases And Review Of Literature, P. Hsu, T. Yang, S. Sheikh-Fayyaz, J. Brody, J. Bandovic, S. Roy, J. Laser, J. E. Kolitz, C. Devoe, X. Zhang
Mantle Cell Lymphoma With In Situ Or Mantle Zone Growth Pattern: A Study Of Five Cases And Review Of Literature, P. Hsu, T. Yang, S. Sheikh-Fayyaz, J. Brody, J. Bandovic, S. Roy, J. Laser, J. E. Kolitz, C. Devoe, X. Zhang
Journal Articles
We present two rare cases of in situ mantle cell lymphoma ("in situ MCL") and three cases of MCL with mantle zone growth pattern (MCL-MZGP). The patients include four males and one female, with a median age of 66 years (range, 52 to 86 years). Two present with isolated lymphadenopathy and three with multiple lymphadenopathy. At presentation, the complete blood count (CBC) and serum lactate dehydrogenase (LDH) are normal in all cases. Histologic examination reveals an in situ pattern in two cases and a mantle zone growth pattern in three cases. The staging bone marrow biopsies show minimal involvement by …
Risk Factors For Gi Adverse Events In A Phase Iii Randomized Trial Of Bevacizumab In First-Line Therapy Of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study, R. A. Burger, M. F. Brady, M. A. Bookman, B. J. Monk, J. L. Walker, H. D. Homesley, J. Fowler, S. C. Rubin, N. Katsumata, S. X. Liang, +4 Additional Authors
Risk Factors For Gi Adverse Events In A Phase Iii Randomized Trial Of Bevacizumab In First-Line Therapy Of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study, R. A. Burger, M. F. Brady, M. A. Bookman, B. J. Monk, J. L. Walker, H. D. Homesley, J. Fowler, S. C. Rubin, N. Katsumata, S. X. Liang, +4 Additional Authors
Journal Articles
Purpose To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in first-line ovarian cancer therapy. Patients and Methods Women with previously untreated advanced disease after surgery were randomly allocated to six cycles of platinum-taxane chemotherapy plus placebo cycles (C)2 to C22 (R1); chemotherapy plus bevacizumab C2 to C6 plus placebo C7 to C22 (R2); or chemotherapy plus bevacizumab C2 to C22 (R3). Patients were evaluated for history or on-study development of potential risk factors for GI AEs defined as grade 2 perforation, fistula, necrosis, or hemorrhage. Results Of 1,873 patients enrolled, 1,759 (94%) …
Academic Pathology: A New Journal, J. M. Crawford
Academic Pathology: A New Journal, J. M. Crawford
Journal Articles
No abstract provided.
The Business Of Genomic Testing: A Survey Of Early Adopters, J. M. Crawford, L. Bry, J. Pfeifer, S. K. Caughron, S. Black-Schaffer, J. A. Kant, J. H. Kaufman
The Business Of Genomic Testing: A Survey Of Early Adopters, J. M. Crawford, L. Bry, J. Pfeifer, S. K. Caughron, S. Black-Schaffer, J. A. Kant, J. H. Kaufman
Journal Articles
Purpose: The practice of "genomic" (or "personalized") medicine requires the availability of appropriate diagnostic testing. Our study objective was to identify the reasons for health systems to bring next-generation Sequencing into their clinical laboratories and to understand the process by which such decisions were made. Such information may be of value to other health systems seeking to provide next-generation sequencing-testing to their patient populations. Methods: A standardized open-ended interview was conducted With the laboratory medical directors and/or department of pathology chairs of 13 different academic institutions in 10 different states. Results: Genomic testing for cancer dominated the institutional decision making, …
Tblr1 As An Androgen Receptor (Ar) Coactivator Selectively Activates Ar Target Genes To Inhibit Prostate Cancer Growth, G. Daniels, Y. Li, L. L. Gellert, A. Zhou, J. Melamed, X. Wu, X. Zhang, D. Zhang, D. Meruelo, S. K. Logan, R. Basch, P. Lee
Tblr1 As An Androgen Receptor (Ar) Coactivator Selectively Activates Ar Target Genes To Inhibit Prostate Cancer Growth, G. Daniels, Y. Li, L. L. Gellert, A. Zhou, J. Melamed, X. Wu, X. Zhang, D. Zhang, D. Meruelo, S. K. Logan, R. Basch, P. Lee
Journal Articles
Androgen receptor (AR), a steroid hormone receptor, is critical for prostate cancer growth. However, activation of AR by androgens can also lead to growth suppression and differentiation. Transcriptional cofactors play an important role in this switch between proliferative and anti-proliferative AR target gene programs. Transducin beta-like-related protein 1 (TBLR1), a core component of the nuclear receptor corepressor complex, shows both corepressor and coactivator activities on nuclear receptors, but little is known about its effects on AR and prostate cancer. We characterized TBLR1 as a coactivator of AR in prostate cancer cells and determined that the activation is dependent on both …